Lytix Biopharma raises $8.36M post-IPO to prep melanoma Phase III
What's the deal? Norwegian clinical-stage biotech Lytix BiopharmaDealroom has a profile for this one. Try Dealroom → has raised US$9.67M (≈$8.36 million) in gross proceeds through a private placement and a retail offering via NordnetDealroom has a profile for this one. Try Dealroom →, both priced at US$0.97 per share. The Oslo-listed company confirmed the completed raise on November 18, 2026.
Who's backing it? The private placement drew US$9.03M, with Lytix's largest shareholders pre-committing. Saturn Invest and HIFO Invest took a combined 3,286,535 shares, TAJ Holding 2,411,535, Jakob HattelandDealroom has a profile for this one. Try Dealroom → Holding 1,411,535, and Per Strand Eiendom 1,036,535. Chief executive officer Øystein Rekdal and chief financial officer Gjest Breistein each took 12,500 shares; the retail offering added US$640.7K.
What's the endgame? Lytix is developing oncolytic therapies that it says kill cancer cells and trigger an immune response, led by ruxotemitide for neoadjuvant melanoma — treatment before surgery. Proceeds fund Phase III readiness, the company's share of the investigator-led ALETTA Phase II study, and advancing LTX-401 toward Phase I.
Why now? The raise follows strong clinical news: the Phase II NeoLIPA study, combining ruxotemitide with pembrolizumab, met its primary endpoint, with detailed data due at ESMO IO in London in mid-December 2026. The capital is meant to prepare the ground for a registrational Phase III trial in melanoma.
What could go wrong? The new money does not fund the pivotal trial itself. "The Phase III study itself will require additional financing and/or a partner," the company said, meaning Lytix must secure more capital or a backer before it can begin.
The signal: The placement follows a US$7.37M raise in January 2026, underlining how small clinical-stage biotechs lean on repeated equity rounds to fund costly late-stage development. For Lytix, strong Phase II data has strengthened the case — but the biggest, most expensive step remains unfunded.
Read more: placera.se
Image credit: Generated with Gemini